01-Nov-2026 09:54:54
AJANTPHARMExpansion
AJANTA PHARMA Q2 FY27 CONCALL: MAINTAINS HIGH-TEENS FY27 REVENUE GROWTH GUIDANCE, 26–28% EBITDA MARGIN & ₹400 CR CAPEX; UPGRADES US GROWTH OUTLOOK TO HIGH SINGLE DIGITS, EXPECTS H2 MARGIN MODERATION
AJANTA PHARMA LIMITED